Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
MIAMI — Longeveron Inc. (NASDAQ: LGVN), a biotechnology company in the clinical stage of developing regenerative medicine, focuses on cellular therapies for serious and chronic aging-related conditions. They have announced their participation in the H.C. Wainwright 26th Annual Global Investment Conference, which will take place from September 9 to September 11, 2024.
Presentation Details
During the conference, Longeveron will share important insights regarding their innovative projects and future plans. Here are the specifics:
Date: September 10, 2024
Time: 5:00 – 5:30 p.m. ET
Accessing the Webcast
Those interested, including investors, can view the webcast of the conference presentation by visiting the “Events and Presentations” section on Longeveron's website. A replay of the webcast will be accessible for 180 days after the event concludes.
About Longeveron Inc.
Longeveron is a leader in biotechnology, dedicated to developing groundbreaking regenerative medicines to address unmet medical needs. Their primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell therapy derived from the bone marrow of young, healthy adult donors. This therapy has several potential mechanisms of action, including promoting vascular health, supporting regeneration, reducing inflammation, and aiding tissue repair. Lomecel-B™ is being investigated for three major indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease (AD), and frailty related to aging.
Regulatory Designations
Importantly, the development programs for Lomecel-B™ have received five significant designations from the U.S. FDA. The HLHS program has been granted Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation, emphasizing the therapy's potential benefits for pediatric patients. The Alzheimer's disease program has earned both the Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation, highlighting its promise as a transformative treatment option.
Commitment to Innovation
Longeveron's dedication to innovation is clear through its comprehensive clinical development strategy, which aims to provide solutions for chronic conditions associated with aging. The company focuses on creating regenerative therapies that not only address symptoms but also seek to alter the underlying disease processes.
Connecting with Longeveron
For additional information, please visit Longeveron's official website. They are also active on various social media platforms, including LinkedIn and X, where they share updates about their innovative treatments and company news.
Investor Relations
Investors with inquiries can contact Derek Cole at Investor Relations Advisory Solutions via email.
Frequently Asked Questions
What is Longeveron Inc. known for?
Longeveron Inc. is recognized for its focus on developing cellular therapies that target chronic aging-related conditions and life-threatening diseases.
What is Lomecel-B™?
Lomecel-B™ is Longeveron’s leading investigational product, an allogeneic medicinal signaling cell therapy thought to offer regenerative benefits for various diseases.
When will Longeveron present at the conference?
Longeveron is set to present on September 10, 2024, from 5:00 – 5:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference.
How can I view the webcast of the presentation?
You can access the webcast in the “Events and Presentations” section of Longeveron’s website, with a replay available for 180 days after the event.
What regulatory designations has Lomecel-B™ received?
Lomecel-B™ has been awarded several key designations, including Orphan Drug, Fast Track, and Rare Pediatric Disease designations for HLHS, as well as Regenerative Medicine Advanced Therapy and Fast Track designations for Alzheimer’s disease.
